S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
S&P 500   4,297.29 (+0.22%)
DOW   33,466.77 (-0.12%)
QQQ   360.45 (+0.61%)
AAPL   173.42 (+1.29%)
MSFT   318.79 (+0.96%)
META   304.78 (+1.52%)
GOOGL   133.50 (+2.02%)
AMZN   129.16 (+1.60%)
TSLA   251.25 (+0.41%)
NVDA   448.69 (+3.15%)
NIO   8.81 (-2.54%)
BABA   86.19 (-0.63%)
AMD   102.33 (-0.48%)
T   14.85 (-1.13%)
F   12.26 (-1.29%)
MU   67.77 (-0.38%)
CGC   0.79 (+1.00%)
GE   109.37 (-1.07%)
DIS   81.02 (-0.04%)
AMC   7.93 (-0.75%)
PFE   33.37 (+0.60%)
PYPL   58.75 (+0.50%)
NFLX   380.71 (+0.82%)
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

$823.71
+0.75 (+0.09%)
(As of 11:15 AM ET)
Compare
Today's Range
$817.14
$833.28
50-Day Range
$727.13
$844.37
52-Week Range
$668.00
$847.50
Volume
94,554 shs
Average Volume
582,649 shs
Market Capitalization
$89.42 billion
P/E Ratio
21.77
Dividend Yield
N/A
Price Target
$900.92

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
9.5% Upside
$900.92 Price Target
Short Interest
Healthy
1.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
1.07mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$27.23 M Sold Last Quarter
Proj. Earnings Growth
2.60%
From $35.42 to $36.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

375th out of 969 stocks

Pharmaceutical Preparations Industry

159th out of 454 stocks


REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Price History

REGN Stock News Headlines

Are Gene Therapy Stocks The Market's Next Big Winners? (REGN)
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Argenx's 28% Surge & Promising Product Propel Investor Confidence (REGN)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Regeneron Pharmaceuticals Stock Earns 85 RS Rating
Top Stock Reports for Amazon.com, Boeing, Regeneron & Others
Analyst Expectations for Regeneron Pharmaceuticals's Future
Is Regeneron Stock Fully Valued At $820?
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Confirmed)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
11,851
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$900.92
High Stock Price Forecast
$1,050.00
Low Stock Price Forecast
$680.00
Forecasted Upside/Downside
+9.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
27 Analysts

Profitability

Net Income
$4.34 billion
Pretax Margin
37.69%

Debt

Sales & Book Value

Annual Sales
$12.67 billion
Cash Flow
$44.53 per share
Book Value
$207.31 per share

Miscellaneous

Free Float
98,973,000
Market Cap
$89.34 billion
Optionable
Optionable
Beta
0.19

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Leonard S. Schleifer M.D.Dr. Leonard S. Schleifer M.D. (Age 70)
    Ph.D., Co-Founder, Pres, CEO & Co-Chairman
    Comp: $7M
  • Dr. George D. Yancopoulos M.D. (Age 63)
    Ph.D., Co-Founder, Pres, Chief Scientific Officer & Co-Chairman
    Comp: $6.59M
  • Mr. Robert E. Landry Jr.Mr. Robert E. Landry Jr. (Age 59)
    Exec. VP of Fin. & CFO
    Comp: $1.84M
  • Dr. Andrew J. Murphy Ph.D. (Age 64)
    Exec. VP of Research
    Comp: $1.62M
  • Mr. Daniel P. Van Plew (Age 50)
    Exec. VP and GM of Industrial Operations & Product Supply
    Comp: $1.95M
  • Ms. Marion E. McCourtMs. Marion E. McCourt (Age 63)
    Exec. VP of Commercial
    Comp: $1.5M
  • Ms. Patrice Gilooly
    Sr. VP of Quality Assurance & Operations
  • Mr. Christopher R. Fenimore CPAMr. Christopher R. Fenimore CPA (Age 52)
    Sr. VP, Head of Accounting & Controller
  • Mr. Gerald Underwood
    Sr. VP of Technical Operations
  • Mr. Bob McCowan
    Sr. VP of IT & Chief Information Officer













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

27 equities research analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $680.00 to $1,050.00. On average, they predict the company's stock price to reach $900.92 in the next twelve months. This suggests a possible upside of 9.5% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 at the beginning of 2023. Since then, REGN stock has increased by 14.1% and is now trading at $822.96.
View the best growth stocks for 2023 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our REGN earnings forecast
.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, November 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported $10.24 earnings per share for the quarter, topping analysts' consensus estimates of $8.48 by $1.76. The biopharmaceutical company had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.02 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 19.19% and a net margin of 33.93%. The company's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the company posted $9.77 earnings per share.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $822.96.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $89.34 billion and generates $12.67 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $37.83 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 11,851 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -